Erastin

571203-78-6

C30H31ClN4O4

DMSO : 6.4 mg/mL (11.70 mM; Need ultrasonic)

Apoptosis

Erastin is a ferroptosis inducer. Erastin binds and inhibits voltage-dependent anion channels (VDAC2/VDAC3). In Vitro: Erastin triggers oxidative, iron-dependent cell death. Treatment of NRAS-mutant HT-1080 fibrosarcoma cells with the RSL molecule erastin (10 uM) results in a time-dependent increase in cytosolic and lipid ROS beginning at 2 hours^[1]. Cell death triggered by erastin is significantly inhibited by antioxidants (e.g., alpha-tocopherol, butylated hydroxytoluene, and beta-carotene) and iron chelators, suggesting that ROS- and iron-dependent signaling is required for erastin-induced ferroptosis. Erastin can directly bind to VDAC2/3 in BJeLR cells. Knockdown of VDAC2 and VDAC3, but not VDAC1, leads to erastin resistance. Erastin has the ability to reduce glutathione level by directly inhibiting cystine/glutamate antiporter system Xc? activity, with activation of the ER stress response^[2]. Erastin potently inhibits HT-29 cell survival. Erastin shows a dose-dependent effect, and 30 uM of erastin displays the most dramatic effect^[3]. In Vivo: Intraperitoneal injection of erastin at well-tolerated doses dramatically inhibits HT-29 xenograft growth in severe combined immunodeficient mice^[3].